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Abstract
Xenotropic murine leukemia virus (MLV)-related virus (XMRV) is a new human retrovirus associated with prostate cancer and
chronic fatigue syndrome. The causal relationship of XMRV infection to human disease and the mechanism of pathogenicity
have not been established. During retrovirus replication, integration of the cDNA copy of the viral RNA genome into the
host cell chromosome is an essential step and involves coordinated joining of the two ends of the linear viral DNA into
staggered sites on target DNA. Correct integration produces proviruses that are flanked by a short direct repeat, which
varies from 4 to 6 bp among the retroviruses but is invariant for each particular retrovirus. Uncoordinated joining of the two
viral DNA ends into target DNA can cause insertions, deletions, or other genomic alterations at the integration site. To
determine the fidelity of XMRV integration, cells infected with XMRV were clonally expanded and DNA sequences at the
viral-host DNA junctions were determined and analyzed. We found that a majority of the provirus ends were correctly
processed and flanked by a 4-bp direct repeat of host DNA. A weak consensus sequence was also detected at the XMRV
integration sites. We conclude that integration of XMRV DNA involves a coordinated joining of two viral DNA ends that are
spaced 4 bp apart on the target DNA and proceeds with high fidelity.
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Introduction
Xenotropic murine leukemia virus (MLV)-related virus
(XMRV) is a new human retrovirus having a 8.65 kbp genome
and shares up to 95% overall nucleotide sequence identity with
other known MLVs [1]. XMRV was first reported to be associated
with prostate cancer from patients homozygous for a defective
variant of RNase L (R462Q), a regulated endoribonuclease for
single-stranded RNA that functions in the antiviral action of
interferon (IFN) [1,2]. The Arg to Gln substitution at amino acid
position 462 (R462Q) of RNase L is a common missense variant
(35% allelic frequency), resulting in a 3-fold decrease in catalytic
activity compared with the wild-type enzyme [3,4]. Consistent
with the observation that the virus is associated with patients
having the homozygous mutant RNASEL genotype, XMRV
replication in vitro is sensitive to IFN-b inhibition [5]. The link
between XMRV and prostate cancer suggests that inherited
defects of RNase L may enhance susceptibility to XMRV, leading
to tumorigenesis. However, detection of XMRV has recently been
reported in prostate samples independent of the RNASEL genotype
[6]. XMRV has also been detected in the blood of patients with
chronic fatigue syndrome [7]. The causal relationships of XMRV
infection to prostate cancer and chronic fatigue syndrome, as well
as the mechanism for virus pathogenicity, have yet to be
established. Additionally, several studies have failed to detect
XMRV in different European cohorts of patients with either
prostate cancer [8] or with chronic fatigue syndrome [9,10,11],
suggesting that either population differences or environmental
factors may modulate the incidence of XMRV infections.
Integration of the cDNA copy of the viral RNA genome is
essential for retroviruses to establish a productive infection (for
reviews, see reference [12]). However, because of its nonspecific
nature, retroviral DNA integration is inherently a mutagenic
event. Many retroviruses, especially members of the gammare-
trovirus genus, can induce tumors as a consequence of integrating
their viral genome into the host cell chromosome and activating
proto-oncogenes via promoter or enhancer insertion, a mechanism
referred to as proviral insertional mutagenesis [13]. XMRV is a
member of the gammaretrovirus family, and does not encode host-
derived oncogenes [1]. Genome-wide analyses of XMRV
integration sites in a human prostate cell line, DU145, and
prostate cancer tissues showed that XMRV integration favors
gene-dense regions and genomic features frequently associated
with structurally open, transcriptional regulatory regions of a
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chromosome, such as transcription start sites, CpG islands, and
DNase hypersensitive sites [14]. The XMRV integration sites in
prostate cancer tissues are further associated with cancer break-
points, common fragile sites, and microRNA genes. However, no
common integration site or integration hotspot has been detected
within or near known proto-oncogenes and tumor suppressor
genes in both acutely infected cells and cancer tissues [14]. Due to
the relatively few integration sites (a total of 14) analyzed thus far
in prostate cancer tissues, the role of XMRV infection in causing
prostate cancer by insertional mutagenesis is still unclear.
Integration of retroviral DNA is catalyzed by the viral enzyme
integrase (IN) and involves sequential steps of DNA breaking and
joining reactions ([12]; and see Fig. 1A). During integrative
recombination, the two ends of the linear viral DNA genome are
joined in a concerted fashion to staggered sites on the opposite
strands of the target DNA. Gap repair of the integration
intermediate results in the formation of a provirus that is flanked
by short direct repeats of target DNA, a hallmark of retroviral
DNA integration [15,16]. The length of the direct repeats, which
varies from 4 to 6 bp among the retroviruses but is invariant for
each particular retrovirus, presumably corresponds to the spacing
of the staggered target DNA sites that are attacked by IN during
integration. Analyses of various proviruses together with the
associated flanking DNA sequences have revealed high integration
Figure 1. Integration of retroviral DNA and generation of short direct repeats flanking the provirus. (A) DNA breaking and joining steps
during integration. Viral and target DNA strands are represented by thick black and parallel lines, respectively, and the viral long terminal repeats
(LTRs) are depicted as grey boxes. Nucleotides at the top and bottom strands are denoted by uppercase and lowercase letters, respectively. During
39-end processing, IN removes two nucleotides from the 39 end of each strand of linear viral DNA so that the viral 39 ends terminate with a conserved
CA dinucleotide. Closed arrowheads denote the positions of strand transfer, a concerted cleavage-ligation reaction during which IN makes a
staggered break in the target DNA. Host DNA repair enzymes fill in the resulting single-stranded gaps, denoted by D1 to D4 in the upper strand and
d1 to d4 in the lower strand of target DNA, and remove the two unpaired nucleotides at the 59 ends of the viral DNA (open arrowheads), thereby
generating the short direct repeats flanking the provirus. (B) A potential pathway for generating a base transversion in the short direct repeat during
XMRV integration. A coordinated integration of the two viral ends occurred at the 4-bp staggered positions as depicted by the closed arrowheads.
During repair of the single-stranded gap adjacent to the upstream LTR, an adenine nucleotide was introduced at the D4 position either by
misincorporation or aberrant processing of the unpaired AA-dinucleotide at the viral 59 end. Subsequent repair of the mismatch resulted in the
observed transversion (denoted by bold types).
doi:10.1371/journal.pone.0010255.g001
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fidelity. For instance, 15 of 15 human immunodeficiency virus
type 1 (HIV-1) integration sites [17,18,19], 8 of 8 MLV integration
sites [20,21,22], and 7 of 7 spleen necrosis virus integration sites
[23,24] have the correct length of the target site duplication.
However, certain mutations of the viral genome or reaction
conditions can lead to uncoordinated integration of the two viral
ends and result in deletions, insertions, or other rearrangements of
the host DNA [25,26,27,28,29]. Therefore, in addition to
insertional mutagenesis, uncoordinated integration of the two
viral ends during integrative recombination may constitute
another mechanism that can cause genomic alterations and
initiate deleterious events in the infected cell. In this study, we have
cloned and determined host DNA sequences flanking XMRV
proviruses. We found that integration of XMRV DNA proceeds
with high fidelity, and consistently produces a 4-bp direct repeat at
the virus-target DNA junctions. Analysis of the 4-bp direct repeats
reveals a weak consensus integration sequence.
Results
Fidelity and length of target site duplication during
XMRV integration
The IN-catalyzed integration of retroviral DNA involves
sequential DNA breaking and joining steps (Fig. 1A). To
determine the length of the target-site duplication during XMRV
integration, we sequenced the stretches of host cell DNA flanking
the long terminal repeat (LTR) at each end of a given provirus,
and then searched for these flanking sequences within the human
genome. To facilitate the analysis, a human prostate cancer cell
line DU145 was infected by XMRV and then clonally expanded.
Ten infected cell clones were analyzed, and a total of 15
integration site sequences flanking both ends of the XMRV
provirus were determined and mapped (Table 1). Three cell clones
(C-6, -7, and -8) contained multiple XMRV proviruses, which may
have resulted from multiple integration events within the same cell
clone or from mixed clonal populations.
Of the 15 XMRV integration sites analyzed, 13 had a 4-bp
target site duplication, one site had a 5-bp duplication (clone C-
10), and one had a 273-bp duplication (clone C-3). Examination of
the viral DNA sequence of the provirus with the 273-bp target site
duplication revealed that the left LTR contained a 5-bp deletion at
the U3 end that includes a CA dinucleotide that is highly
conserved in retroviruses [12]. Deletion or mutation of the CA-
dinucleotide in the viral donor DNA substrates significantly
reduces the efficiency of coordinated integration of two donor
molecules into a target DNA [28,30,31,32,33]. The U3 end
deletion in the left LTR might cause an uncoordinated integration
of the two XMRV DNA ends, resulting in staggered breaks that
were 273-bp apart. For the 13 proviral integration sites with a 4-bp
duplication, 12 had duplication sequences that matched correctly
with human genomic DNA sequences. The remaining integration
site (from clone C-8) contained a T to A transversion at the
position 4 within the direct repeat flanking the left LTR (59-
TAAA), while the direct repeat flanking the right LTR (59-TAAT)
matched correctly with the human genomic DNA (59-TAAT).
Since mismatches in the genome would most likely be repaired by
host enzymes before integration, we speculate that the transversion
was produced by base misincorporation during gap filling or
aberrant processing of the unpaired nucleotides at the viral 59 end,
followed by mismatch repair that fixed the mutation (Fig. 1B).
In addition to the length of the direct repeats, analysis of the 15
integration site sequences showed that all viral sequences, with the
exception of the left LTR end of the proviral clone C-3, were
terminated with the conserved CA dinucleotide at the 39 end (data
not shown), indicating that the viral DNA ends were correctly
cleaved by IN [12]. Based on our analysis that 87% (13 of 15) of
the proviruses had a correct 4-bp direct repeat at the integration
site, we conclude that the majority of XMRV integration reactions
involve a concerted joining of two viral DNA ends that are spaced
4 bp apart on the target DNA.
Base composition surrounding XMRV integration sites
Genome-wide analyses of virus-target DNA junctions reveal a
weak consensus integration sequence that is nonetheless unique for
each retrovirus examined [34,35,36,37,38]. This consensus
integration sequence is generally palindromic. For instance, the
consensus integration sequence for HIV-1 and MLV are 59-
GTWAC and 59-VTAB, respectively (using standard International
Union of Biochemistry base codes: B = C, G, or T; V = A, C, or
G; W = A or T) [34,35,37,38]. To determine the base
composition surrounding the XMRV integration site, the target
DNA sequences flanking the proviruses were aligned relative to the
integration site (between position 21 and D1; Fig. 2), and the
nucleotide frequency of the 4-bp direct repeat (positions D1 to D4;
Fig. 2) and the positions 10 bp upstream (positions 21 to 210)
and 10 bp downstream (positions +1 to +10) of the direct repeat
were calculated. In addition to the 13 integration site sequences
from the cell clones, the analysis included a dataset containing 472
XMRV integration sites from acutely infected DU145 cells and 14
integration sites from human prostate cancer tissues [14].
Comparison of the nucleotide frequency at each position to the
value of a random dataset generated in silico led to identification of
a 59-CTVB consensus sequence (P,0.0001). Among all the
retroviruses analyzed, the consensus integration site sequence of
Table 1. Positions of XMRV integration sites and lengths of
the target site sequence duplication.
Cell Clones
Integration Site*
(chromosome; nucleotide position)
Duplication
Length (bp)
C-1 13; 77,016,416 (+) 4
C-3 2; 33,211,657 (+) 273 {
C-4 5; 34,622,591 (+) 4
C-5 10; 25,254,665 (+) 4
C-6 1; 19,788,033 (+) 4
2; 19,118,533 (+) 4
C-7 4; 109,005,770 (2) 4
5; 64,073,721 (+) 4
9; 94,680,941 (2) 4
19; 2,119,434 (+) 4
C-8 1; 8,643,694 (+) 4
1; 9,804,426 (+) 4 y
C-9 2; 109,669,551 (2) 4
C-10 6; 30,858,925 (+) 5
C-12 16; 67,648,746 (2) 4
*The nucleotide position corresponds to the position of viral DNA insertion at
the top strand of the chromosome indicated. Symbols + and – within the
parenthesis indicate the orientation of the viral transcription is the same and
opposite, respectively, to the polarity of the top strand. GenBank accession
numbers for the integration site sequences are GU816075 to GU816104.
{The left LTR of the provirus contains a 5-bp deletion that includes the
conserved CA dinucleotide at the viral end.
yThe target DNA contains a T to A transversion immediately adjacent to the left
LTR (position 4).
doi:10.1371/journal.pone.0010255.t001
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XMRV is most similar to that of MLV [34,35,38]. Both XMRV
and MLV generate a 4-bp target site duplication with thymine
favored at the D2 position and adenine disfavored at the D4
position. In addition, thymine was disfavored at the D1 position
for both XMRV and MLV. At position D3 of the XMRV
integration site sequence, although the only statistical significance
at P,0.0001 was the underrepresentation of thymine, adenine was
significantly favored at P,0.005. In addition to the 4-bp direct
repeat, many positions upstream and downstream of the direct
repeat had nucleotide frequencies that were significantly overrep-
resented (e.g. cytosine and guanine at positions +3 and +9,
respectively) or underrepresented (e.g. guanine at position 22)
when compared to the random in silico control. Furthermore, some
of the positions with significantly different representation showed
symmetry, such as adenine being favored at position +2 and the
corresponding thymine being favored at position 22. Other
positions exhibiting a distinct nucleotide preference, however, did
not show this symmetry; for example, cytosine was favored at
position +3, but guanine was not favored at position 23.
Discussion
XMRV is a newly discovered gammaretrovirus that has been
associated with prostate cancer and chronic fatigue syndrome in
humans [1]. An important question is whether XMRV has a
causal role in initiation or progression of either of these two
diseases. In this study, we investigated if integration of XMRV
DNA into the host cell chromosome can cause genetic alterations
that may subsequently lead to human disease. During integration,
the two ends of the linear viral DNA are joined to staggered sites
on the opposite strands of the target DNA [12]. Subsequent strand
separation and gap repair lead to the presence of short direct
repeats flanking the proviral DNA [15,16]. Therefore, the length
of the direct repeats presumably corresponds to the spacing of the
two viral ends on target DNA during integrative recombination
catalyzed by IN. Analyses of various proviruses have revealed that
the length of target site duplication, though varying from 4 to 6 bp
among the different retroviruses examined, is invariant for each
particular retrovirus [12,23,39]. The high fidelity of the direct
repeat length supports the notion that IN multimers form a stable
complex with viral and target DNA and catalyze coordinated
processing and integration of the two viral DNA ends
[30,33,40,41,42]. In addition, reaction conditions in vitro and in
vivo that promote uncoordinated integration of the two ends often
produce deletions and duplications of various lengths in the target
DNA [25,26,27,28,29,31,39,43]. Since the majority of the
integrated XMRV contain viral sequences that terminate with
the conserved CA dinucleotide and are flanked by a 4-bp direct
repeat of target DNA sequence, we conclude that the two viral
DNA ends are correctly processed and joined in a coordinated
manner to target DNA by IN during XMRV integration.
Although retroviruses can access most of the host genome for
integration, selection of particular target sites is not random, and
the frequency of use of specific sites varies considerably, with some
sites being preferred up to several hundred times greater than
random [44,45,46]. The mechanism that determines target site
specificity is not well understood, and is likely affected by multiple
factors [47,48]. Both in vitro and in vivo studies have implicated IN
as one important determinant in specifying a chromosomal or
DNA site for integration. INs of different retroviruses exhibit
significant differences in the distribution and preference of
integration into an identical target substrate in vitro [49,50,51],
and in vivo, a chimeric HIV that encodes IN from MLV integrates
preferentially into chromosomal features favored by MLV (i.e.
transcription start sites and CpG islands) instead of transcription
units as favored by HIV-1 [39]. Although primary DNA sequence
is likely not a dominant factor in determining target site specificity,
genome-wide analyses of virus-target DNA junctions reveal
the presence of weak consensus integration sequences, which
are generally palindromic and unique for each retrovirus
[34,35,36,37,38,52,53,54,55]. A weak palindromic consensus
sequence is also detected among the XMRV integration sites.
We hypothesize that integration of retroviral DNA into a host
DNA site depends on the specific interaction between IN and
target DNA sequences, resulting in each retrovirus having its own
unique, though weak, consensus sequence. The consensus
sequence for each retrovirus may be a result of favorable
interactions between the DNA bases and certain amino acid
residues of IN, or may reflect the amenability of the sequence in
adopting particular DNA structures favorable for IN binding. For
instance, a common mechanism for stimulating HIV-1 integration
is DNA bending, which creates a widened major groove at the
outer curved face that is favorable for integration [49,56,57,58,59].
The site and fidelity of integration have significant implications
for the fate of both the virus and the host cell. Although the present
study shows that XMRV integration proceeds with high fidelity,
further analysis of additional XMRV integration sites in human
tissues would be necessary to clarify whether insertional mutagen-
esis plays a pathogenic role during XMRV infection. Many viruses
Figure 2. Base composition surrounding XMRV integration sites. Base compositions of the 4-bp target site duplication (positions D1 to D4;
demarcated by the thick vertical lines) and 10 bp upstream (positions 21 to 210) and downstream (positions +1 to +10) of the direct repeat were
calculated. The datasets include the 13 integration sites with correct 4-bp direct repeat (Table 1), 472 integration sites from acutely infected DU145
cells (GenBank accession numbers EU981292 to EU981799) and 14 integration sites from human prostate cancer tissues (GenBank accession numbers
EU981800 to EU981813) [14]. Integration occurs between positions 21 and D1 on the top strand, and between positions D4 and +1 on the bottom
strand (blue arrows). Any base in a position that is significantly overrepresented than the random dataset (P,0.0001) is highlighted in green, while
any base in a position that is significantly underrepresented than the random dataset (P,0.0001) is highlighted in red.
doi:10.1371/journal.pone.0010255.g002
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from the gammaretrovirus genus of the Retroviridae family, such as
MLV, feline leukemia virus, and koala retrovirus, are responsible
for leukemogenesis and other diseases in their respective host
species [60]. Therefore, the recent evidence of authentic infections
of humans by XMRV and the association of XMRV infection
with prostate cancer and chronic fatigue syndrome [1,6,7] are
alarming and warrant further investigations to determine the
causal relationship and pathogenic mechanisms.
Materials and Methods
Host DNA sequences flanking the XMRV provirus
To determine the length and base composition of the target
sequence duplication produced by XMRV integration, ten single-
clonal (isogenic) populations of XMRV-infected cells were
prepared. Plasmid VP62/pcDNA3.1(2) containing the molecular
clone of XMRV [5] was transfected with Lipofectamine 2000
(Invitrogen) into DU145 cells. The transfected cells were cultured
with complete RPMI 1640 media for 3 weeks, trypsinized,
diluted, and plated in 96-well plates so that the calculated
number of cells per well on average would be 0.15, 0.45, 1.5, 4.5
and 15. The media from wells with a single colony were assayed
for reverse transcriptase (RT) activities after 17 to 24 days. Based
on high RT activities, ten clones were chosen for integration site
analysis. For each clonal population, the cellular DNA sequence
at the right LTR-host DNA junction was determined using the
linker ligation-mediated PCR assay as described below. Based on
the sequence information of the right LTR-host DNA junction,
the left LTR-host DNA junction was amplified by nested PCR
using forward primers that anneal to positions upstream of the
left LTR-host DNA junction and reverse primers that anneal to
sequences downstream and within the left LTR. XMRV613R
(59-GATCGCCGGCCGGCTTA), which is complementary to nt
positions 597 to 613 of XMRV, and XMRV165R (59-
CCTGACTACAGATATCCTGTTT), which is complementary
to nt positions 143 to 165, were used as reverse primers for the
first and second PCRs, respectively. The PCR product was
electrophoresed on a 1.5% agarose gel, and the expected size of
DNA band was excised from the gel and extracted using a gel
extraction kit (Qiagen). Extracted DNA was cloned into a
pCR-Blunt vector using a Zero Blunt PCR Cloning Kit
(Invitrogen).
Linker ligation-mediated PCR assay for cloning XMRV
integration sites
The genomic DNA from XMRV-infected cells was isolated with
a QIAamp DNA Mini Kit (Qiagen) following the manufacturer’s
instruction. The assay for determining XMRV integration sites in
DU145 cells was performed as described previously [14]. Briefly,
genomic DNA from XMRV-infected DU145 cells was digested
with Pst I, which cuts once in the XMRV genome at nucleotide
(nt) position 7,534 and produces on average 4-kbp DNA
fragments. After digestion, DNA was denatured and annealed
with a biotinylated primer, bXMRV7938 (59-biotin-ATCC-
TACTCTTCGGACCCTGT), which is complementary to nt
positions 7,938 to 7,958 within the env gene (about 160 bp upstream
of the right LTR). The annealed primer was extended using the
PicoMaxx High Fidelity PCR system (Stratagene) to produce
biotinylated double-stranded DNA containing the viral-human
DNA junction region. The biotinylated DNA product was then
isolated by binding to streptavidin-agarose Dynabeads (Dynal), and
digested with TaqaI (59-TQCGA), a 4-bp cutter that does not cleave
the viral DNA portion of the biotinylated DNA. Digestion of the
human genomic DNA with TaqaI produces on average 1.9-kbp
DNA fragments [61]. After digestion, the integration site-containing
DNAwas ligated with TaqLinker, which was prepared by annealing
BHLinkA (59-CGGATCCCGCATCATATCTCCAGGTGTGA-
CAGTTT) with TaqLinkS (59-CACCTGGAGATATGATG-
CGGGATC). The TaqLinker contains a 2-nt 59-overhang (in bold
type) complementary to the TaqaI -digested biotinylated DNA. The
linker-ligated DNA product was amplified by a two-step PCR
process. The first PCR was carried out using primers XMRV8415F
(59-AACCAATCAGCTCGCTTCTC) and Linker1 (59-TAA-
CTGTCACACCTGGAGATA) in a final volume of 300 ml with
0.5 mM of each primer, 0.2 mM of dNTPs, and 12 U Pfu DNA
polymerase (Stratagene) under the following condition: 2 min of
preincubation at 94uC, followed by 29 cycles at 94uC for 30 s, 58uC
for 30 s, and 72uC for 4 min. The PCR product was purified using a
PCR Purification Kit (Qiagen), and was used as the template for the
second PCR with two nested primers, XMRV8535F (59-
CGGGTACCCGTGTTCCCAATA) and Linker2 (59-TAGA-
TATGATGCGGGATCCG), which anneal downstream of
XMRV8415F and Linker1 binding sites, respectively. The
condition for the second PCR was identical to the first PCR except
being conducted with only 18 cycles. The second PCR product was
electrophoresed on a 1.5% agarose gel and DNA bands between
200 bp to 2 kbp were extracted and cloned into a pCR-Blunt vector
using a Zero Blunt PCR Cloning Kit (Invitrogen).
Integration site sequence determination and data
analysis
The sequence of the cloned DNA was determined by dideoxy
sequencing, and sequencing ambiguities were resolved by repeated
sequencing on both strands. The authenticity of the integration
site sequence were verified by the following criteria: (i) the
sequence contained both XMRV LTR and linker sequence, (ii) a
match to the human genome begining after the end of the LTR
(59-…CA-39) and ending with the linker sequence, and (iii) the host
DNA region (containing 20 or more nucleotides) from the putative
integration site sequence showed 96% or greater identity to the
human genomic sequence. The authenticated integration site
sequences were then mapped to the human genome hg18
[University of California, Santa Cruz (UCSC) March 2006 freeze;
National Center for Biotechnology Information (NCBI) Build
36.1] using BLASTN program (http://www.ensembl.org) or
BLAT (UCSC; http://genome.ucsc.edu).
To determine nucleotide preference at integration sites, the
target DNA sequences flanking the viral-host DNA junctions were
aligned relative to the point of viral DNA integration. The XMRV
integration site datasets used to determine nucleotide preference
include the 13 correct integration sites listed in Table 1 (GenBank
accession numbers GU816075, GU816076, GU816079 to
GU816100, GU816103, GU816104), 472 integration sites from
acutely infected DU145 cells (GenBank accession numbers
EU981292 to EU981799) [14], and 14 integration sites from
human prostate cancer tissues (GenBank accession numbers
EU981800 to EU981813) [14]. The nucleotide frequency at each
position was calculated and compared to values obtained from a
set of 10,000 random positions generated in silico by choosing a
random number between 1 and 3,093,120,360, which represents
the total length of the 22 autosomal chromosomes plus the X-sex
chromosome of the human genome. The nucleotide frequencies of
the random dataset are 29.8%, 20.4%, 20.5%, and 29.3% for A,
C, G, and T, respectively. Statistical difference of nucleotide
frequency between XMRV integration site sequences and the
random dataset was analyzed at each position using a chi-square
test at P,0.0001.
Fidelity of XMRV Integration
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Nucleotide sequences accession numbers
The GenBank accession numbers for integration site sequences
from the ten XMRV-infected cell clones listed in Table 1 are
GU816075 to GU816104.
Acknowledgments
We thank Thomas A. Wilkinson for comments on the manuscript.
Author Contributions
Conceived and designed the experiments: RHS SAC. Performed the
experiments: SK AR BD RR. Analyzed the data: SK AR SAC.
Contributed reagents/materials/analysis tools: BD RHS. Wrote the paper:
SK RHS SAC.
References
1. Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G, et al. (2006)
Identification of a novel Gammaretrovirus in prostate tumors of patients
homozygous for R462Q RNASEL variant. PLoS Pathog 2: e25.
2. Silverman RH (2003) Implications for RNase L in prostate cancer biology.
Biochemistry 42: 1805–1812.
3. Casey G, Neville PJ, Plummer SJ, Xiang Y, Krumroy LM, et al. (2002)
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer
cases. Nat Genet 32: 581–583.
4. Xiang Y, Wang Z, Murakami J, Plummer S, Klein EA, et al. (2003) Effects of
RNase L mutations associated with prostate cancer on apoptosis induced by
29,59-oligoadenylates. Cancer Res 63: 6795–6801.
5. Dong B, Kim S, Hong S, Das Gupta J, Malathi K, et al. (2007) An infectious
retrovirus susceptible to an IFN antiviral pathway from human prostate tumors.
Proc Natl Acad Sci USA 104: 1655–1660.
6. Schlaberg R, Choe DJ, Brown KR, Thaker HM, Singh IR (2009) XMRV is
present in malignant prostatic epithelium and is associated with prostate cancer,
especially high-grade tumors. Proc Natl Acad Sci USA 106: 16351–16356.
7. Lombardi VC, Ruscetti FW, Das Gupta J, Pfost MA, Hagen KS, et al. (2009)
Detection of an infectious retrovirus, XMRV, in blood cells of patients with
chronic fatigue syndrome. Science 326: 585–589.
8. Hohn O, Krause H, Barbarotto P, Niederstadt L, Beimforde N, et al. (2009)
Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in
German prostate cancer patients. Retrovirology 6: 92.
9. Erlwein O, Kaye S, McClure MO, Weber J, Wills G, et al. (2010) Failure to
detect the novel retrovirus XMRV in chronic fatigue syndrome. PLoS ONE 5:
e8519.
10. Groom H, Boucherit V, Makinson K, Randal E, Baptista S, et al. (2010)
Absence of xenotropic murine leukaemia virus-related virus in UK patients with
chronic fatigue syndrome. Retrovirology 7: 10.
11. van Kuppeveld FJM, de Jong AS, Lanke KH, Verhaegh GW, Melchers WJG,
et al. (2010) Prevalence of xenotropic murine leukaemia virus-related virus in
patients with chronic fatigue syndrome in the Netherlands: retrospective analysis
of samples from an established cohort. BMJ 340: c1018.
12. Brown PO (1997) Integration. In: Coffin JM, Hughes SH, Varmus HE, eds.
Retroviruses. Cold Spring Harbor: Cold Spring Harbor Laboratory Press. pp
161–203.
13. Mikkers H, Berns A (2003) Retroviral insertional mutagenesis: tagging cancer
pathways. Adv Cancer Res 88: 53–99.
14. Kim S, Kim N, Dong B, Boren D, Lee SA, et al. (2008) Integration site
preference of xenotropic murine leukemia virus-related virus, a new human
retrovirus associated with prostate cancer. J Virol 82: 9964–9977.
15. Yoder KE, Bushman FD (2000) Repair of gaps in retroviral DNA integration
intermediates. J Virol 74: 11191–11200.
16. Li L, Olvera JM, Yoder KE, Mitchell RS, Butler SL, et al. (2001) Role of the
non-homologous DNA end joining pathway in the early steps of retroviral
infection. Embo J 20: 3272–3281.
17. Muesing MA, Smith DH, Cabradilla CD, Benson CV, Lasky LA, et al. (1985)
Nucleic acid structure and expression of the human AIDS/lymphadenopathy
retrovirus. Nature 313: 450–458.
18. Vincent KA, York HD, Quiroga M, Brown PO (1990) Host sequences flanking
the HIV provirus. Nucleic Acids Res 18: 6045–6047.
19. Vink C, Groenink M, Elgersma Y, Fouchier RA, Tersmette M, et al. (1990)
Analysis of the junctions between human immunodeficiency virus type 1 proviral
DNA and human DNA. J Virol 64: 5626–5627.
20. Shoemaker C, Goff S, Gilboa E, Paskind M, Mitra SW, et al. (1980) Structure of
a cloned circular Moloney murine leukemia virus DNA molecule containing an
inverted segment: implications for retrovirus integration. Proc Natl Acad Sci
USA 77: 3932–3936.
21. Shoemaker C, Hoffman J, Goff SP, Baltimore D (1981) Intramolecular
integration within Moloney murine leukemia virus. J Virol 40: 164–172.
22. Horowitz JM, Holland GD, King SR, Risser R (1987) Germ line integration of a
murine leukemia provirus into a retroviruslike sequence. J Virol 61: 701–707.
23. Shimotohno K, Temin HM (1980) No apparent nucleotide sequence specificity
in cellular DNA juxtaposed to retrovirus proviruses. Proc Natl Acad Sci USA 77:
7357–7361.
24. Shimotohno K, Mizutani S, Temin HM (1980) Sequence of retrovirus provirus
resembles that of bacterial transposable elements. Nature 285: 550–554.
25. Moreau K, Torne-Celer C, Faure C, Verdier G, Ronfort C (2000) In vivo
retroviral integration: fidelity to size of the host DNA duplication might be
reduced when integration occurs near sequences homologous to LTR ends.
Virology 278: 133–136.
26. Taganov K, Daniel R, Katz RA, Favorova O, Skalka AM (2001) Character-
ization of retrovirus-host DNA junctions in cells deficient in nonhomologous-end
joining. J Virol 75: 9549–9552.
27. Oh J, Chang KW, Alvord WG, Hughes SH (2006) Alternate polypurine tracts
affect Rous sarcoma virus integration in vivo. J Virol 80: 10281–10284.
28. Oh J, Chang KW, Hughes SH (2006) Mutations in the U5 sequences adjacent to
the primer binding site do not affect tRNA cleavage by Rous sarcoma virus
RNase H but do cause aberrant integrations in vivo. J Virol 80: 451–459.
29. Vatakis DN, Kim S, Kim N, Chow SA, Zack JA (2009) Human immunode-
ficiency virus integration efficiency and site selection in quiescent CD4+ T cells.
J Virol 83: 6222–6533.
30. Aiyar A, Hindmarsh P, Skalka AM, Leis J (1996) Concerted integration of linear
retroviral DNA by the avian sarcoma virus integrase in vitro: dependence on
both long terminal repeat termini. J Virol 70: 3571–3580.
31. Goodarzi G, Pursley M, Felock P, Witmer M, Hazuda D, et al. (1999) Efficiency
and fidelity of full-site integration reactions using recombinant simian
immunodeficiency virus integrase. J Virol 73: 8104–8111.
32. Hindmarsh P, Ridky T, Reeves R, Andrake M, Skalka AM, et al. (1999) HMG
protein family members stimulate human immunodeficiency virus type 1 and
avian sarcoma virus concerted DNA integration in vitro. J Virol 73: 2994–3003.
33. Li M, Craigie R (2005) Processing of viral DNA ends channels the HIV-1
integration reaction to concerted integration. J Biol Chem 280: 29334–29339.
34. Holman AG, Coffin JM (2005) Symmetrical base preferences surrounding HIV-
1, avian sarcoma/leukosis virus, and murine leukemia virus integration sites.
Proc Natl Acad Sci USA 102: 6103–6107.
35. Lewinski MK, Bisgrove D, Shinn P, Chen H, Hoffmann C, et al. (2005)
Genome-wide analysis of chromosomal features repressing human immunode-
ficiency virus transcription. J Virol 79: 6610–6619.
36. Berry C, Hannenhalli S, Leipzig J, Bushman FD (2006) Selection of target sites
for mobile DNA integration in the human genome. PLoS Comput Biol 2: e157.
37. Kim S, Kim Y, Liang T, Sinsheimer JS, Chow SA (2006) A high-throughput
method for cloning and sequencing HIV-1 integration sites. J Virol 80:
11313–11321.
38. Derse D, Crise B, Li Y, Princler G, Lum N, et al. (2007) Human T-cell leukemia
virus type 1 integration target sites in the human genome: comparison with those
of other retroviruses. J Virol 81: 6731–6741.
39. Lewinski MK, Yamashita M, Emerman M, Ciuffi A, Marshall H, et al. (2006)
Retroviral DNA integration: viral and cellular determinants of target-site
selection. PLoS Pathog 2: 611–622.
40. Murphy JE, Goff SP (1992) A mutation at one end of Moloney murine leukemia
virus DNA blocks cleavage of both ends by the viral integrase in vivo. J Virol 66:
5092–5095.
41. Moreau K, Faure C, Violot S, Gouet P, Verdier G, et al. (2004) Mutational
analyses of the core domain of avian leukemia and sarcoma viruses integrase:
critical residues for concerted integration and multimerization. Virology 318:
566–581.
42. Li M, Mizuuchi M, Burke TR, Jr., Craigie R (2006) Retroviral DNA integration:
reaction pathway and critical intermediates. Embo J 25: 1295–1304.
43. Sinha S, Pursley MH, Grandgenett DP (2002) Efficient concerted integration by
recombinant human immunodeficiency virus type 1 integrase without cellular or
viral cofactors. J Virol 76: 3105–3113.
44. Craigie R (1992) Hotspots and warm spots: integration specificity of retro-
elements. Trends Genet 8: 187–190.
45. Withers-Ward ES, Kitamura Y, Barnes JP, Coffin JM (1994) Distribution of
targets for avian retrovirus DNA integration in vivo. Genes Dev 8: 1473–1487.
46. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, et al. (2002) HIV-1
integration in the human genome favors active genes and local hotspots. Cell
110: 521–529.
47. Holmes-Son ML, Appa RS, Chow SA (2001) Molecular genetics and target site
specificity of retroviral integration. Adv Genet 43: 33–69.
48. Bushman F, Lewinski M, Ciuffi A, Barr S, Leipzig J, et al. (2005) Genome-wide
analysis of retroviral DNA integration. Nat Rev Microbiol 3: 848–858.
49. Pryciak PM, Varmus HE (1992) Nucleosomes, DNA-binding proteins, and DNA
sequence modulate retroviral integration target site selection. Cell 69: 769–780.
50. Katzman M, Sudol M (1995) Mapping domains of retroviral integrase
responsible for viral DNA specificity and target site selection by analysis of
chimeras between human immunodeficiency virus type 1 and visna virus
integrases. J Virol 69: 5687–5696.
Fidelity of XMRV Integration
PLoS ONE | www.plosone.org 6 April 2010 | Volume 5 | Issue 4 | e10255
51. Shibagaki Y, Chow SA (1997) Central core domain of retroviral integrase is
responsible for target site selection. J Biol Chem 272: 8361–8369.
52. Hacker CV, Vink CA, Wardell TW, Lee S, Treasure P, et al. (2006) The
integration profile of EIAV-based vectors. Mol Ther 14: 536–545.
53. Kang Y, Moressi CJ, Scheetz TE, Xie L, Tran DT, et al. (2006) Integration site
choice of a feline immunodeficiency virus vector. J Virol 80: 8820–8823.
54. Moalic Y, Blanchard Y, Felix H, Jestin A (2006) Porcine endogenous retrovirus
integration sites in the human genome: features in common with those of murine
leukemia virus. J Virol 80: 10980–10988.
55. Nowrouzi A, Dittrich M, Klanke C, Heinkelein M, Rammling M, et al. (2006)
Genome-wide mapping of foamy virus vector integrations into a human cell line.
J Gen Virol 87: 1339–1347.
56. Muller HP, Varmus HE (1994) DNA bending creates favored sites for retroviral
integration: an explanation for preferred insertion sites in nucleosomes. EMBO J
13: 4704–4714.
57. Taganov KD, Cuesta I, Daniel R, Cirillo LA, Katz RA, et al. (2004) Integrase-
specific enhancement and suppression of retroviral DNA integration by
compacted chromatin structure in vitro. J Virol 78: 5848–5855.
58. Bor Y-C, Bushman FD, Orgel L (1995) In vitro integration of human
immunodeficiency virus type 1 cDNA into targets containing protein-induced
bends. Proc Natl Acad Sci USA 92: 10334–10338.
59. Wang GP, Ciuffi A, Leipzig J, Berry CC, Bushman FD (2007) HIV integration
site selection: Analysis by massively parallel pyrosequencing reveals association
with epigenetic modifications. Genome Res 17: 1186–1194.
60. Rosenberg N, Jolicoeur P (1997) Retroviral pathogenesis. In: Coffin JM,
Hughes SH, Varmus HE, eds. Retroviruses. Cold Spring Harbor: Cold Spring
Harbor Laboratory Press. pp 475–586.
61. Gabriel R, Eckenberg R, Paruzynski A, Bartholomae CC, Nowrouzi A, et al.
(2009) Comprehensive genomic access to vector integration in clinical gene
therapy. Nat Med 15: 1431–1436.
Fidelity of XMRV Integration
PLoS ONE | www.plosone.org 7 April 2010 | Volume 5 | Issue 4 | e10255
